What is MapLight Therapeutics, Inc. 's depreciation?

MapLight Therapeutics, Inc. (MPLT) reported depreciation of $162K in Q1 2026.

How has MapLight Therapeutics, Inc. 's depreciation changed year-over-year?

MapLight Therapeutics, Inc. 's depreciation decreased by 2.4% year-over-year, from $166K to $162K.

MapLight Therapeutics, Inc. MPLT Depreciation

Depreciation at other companies

Acadia PharmaceuticalsACAD

——

AbbVieABBV

——

Taysha Gene Therapies, Inc.TSHA

——

Catalyst PharmaceuticalCPRX

——

Praxis Precision Medicines, Inc.PRAX

——

Maze Therapeutics, Inc. Common StockMAZE

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's depreciation?: MapLight Therapeutics, Inc. (MPLT) reported depreciation of $162K in Q1 2026.
How has MapLight Therapeutics, Inc. 's depreciation changed year-over-year?: MapLight Therapeutics, Inc. 's depreciation decreased by 2.4% year-over-year, from $166K to $162K.